Biomarkers in the setting of benign prostatic HyperplasiaInduced lower urinary tract symptoms: What an interventional radiologist needs toKnow.

Biomarkers in the setting of benign prostatic HyperplasiaInduced lower urinary tract symptoms: What an interventional radiologist needs toKnow. Br J Radiol. 2020 Jul 24;:20200484 Authors: Young S, Gasparetto A, Jalaeian H, Golzarian J Abstract With increasing evidence to support prostate artery embolization (PAE) in the treatment of benign prostatic hyperplasia (BPH) induced lower urinary tract symptoms (LUTS), Interventional Radiologists have begun to play an important role in the management of these patients. One area of knowledge needed when developing a PAE practice, is knowledge of prostate specific antigen (PSA) and other biomarkers utilized to detect prostate cancer in this population and what rolethey should play in the work up and follow up of patients presenting with presumed BPH induced LUTS. Furthermore, understanding how to evaluate presumed BPH induced LUTS and stratify the risk of prostate cancer is an important skill to develop. The goal of this review is to provide Interventional Radiologists who have begun or aim to begin a PAE practice with the information they need to know regarding PSA levels and prostate cancer risk stratification for this patient population. PMID: 32706988 [PubMed - as supplied by publisher]
Source: The British Journal of Radiology - Category: Radiology Authors: Tags: Br J Radiol Source Type: research